Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial.
Saved in:
| Title: | Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial. |
|---|---|
| Authors: | Cheng Y; Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China., Qin T; BeOne Medicines, Ltd, Beijing, China., Chen C; BeOne Medicines, Ltd, Beijing, China., B Barnes F; BeOne Medicines, Ltd, San Carlos, CA, USA., Barnes G; BeOne Medicines, Ltd, San Carlos, CA, USA. |
| Source: | Current medical research and opinion [Curr Med Res Opin] 2025 Dec; Vol. 41 (12), pp. 2357-2367. Date of Electronic Publication: 2026 Jan 30. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1473-4877 |
|---|---|
| DOI: | 10.1080/03007995.2026.2620691 |
